Identification
- Summary
Ambroxol is a medication indicated for airway secretion clearance therapy.
- Generic Name
- Ambroxol
- DrugBank Accession Number
- DB06742
- Background
Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body’s natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Ambroxol (DB06742)
- Weight
- Average: 378.108
Monoisotopic: 375.978589 - Chemical Formula
- C13H18Br2N2O
- Synonyms
- Ambroxol
- Ambroxolum
- Bisolvon metabolite vIII
- Bromhexine metabolite vIII
- Bromhexine-metabolite vIII
- Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (E)-
- N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol
- N-(2-Amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanol
- trans-4-((2-Amino-3,5-dibromobencil)amino)ciclohexanol
- trans-4-((2-Amino-3,5-dibromobenzyl)amine)cyclohexanol
- trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol
- External IDs
- NA-872
Pharmacology
- Indication
Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Ambroxol is a mucolytic agent. Excessive Nitric oxide (NO) is associated with inflammatory and some other disturbances of airways function. NO enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. It is also possible that the inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion, therefore it lowers the phlegm viscosity and improves the mucociliary transport of bronchial secretions.
- Absorption
Rapid and almost complete.
- Volume of distribution
Not Available
- Protein binding
Approximately 90%
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
7-12 hours
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Ambroxol can be increased when it is combined with Abametapir. Abemaciclib The risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Ambroxol. Abiraterone The risk or severity of methemoglobinemia can be increased when Abiraterone is combined with Ambroxol. Acetaminophen The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Ambroxol. Acetazolamide The risk or severity of methemoglobinemia can be increased when Acetazolamide is combined with Ambroxol. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Ambroxol hydrochloride CC995ZMV90 23828-92-4 QNVKOSLOVOTXKF-PFWPSKEQSA-N - International/Other Brands
- Ambrolex (GlaxoSmithKline Inc.) / Ambrox (Square) / Tabcin
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image AMCOSOL SYRUP 30MG/5ML Syrup Oral PRIME PHARMACEUTICAL SDN. BHD. 2020-09-08 Not applicable Malaysia 
AMCOSOL TABLET 30MG Tablet Oral PRIME PHARMACEUTICAL SDN. BHD. 2020-09-08 Not applicable Malaysia AMSOLVAN ORAL SOLUTION 30mg/5ml Solution Oral XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD 2020-09-08 Not applicable Malaysia AMTUSS (Syrup ) Syrup 30 mg/5ml Oral MEDISPEC (M) SDN.BHD 2020-09-08 Not applicable Malaysia AMTUSS 30 MG TABLET Tablet 30 mg Oral MEDISPEC (M) SDN.BHD 2020-09-08 Not applicable Malaysia - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BRONSINEX JARABE Ambroxol hydrochloride (300 mg) + Clenbuterol (0.2 mg) Syrup Oral GONHER FARMACEUTICA LTDA 2009-06-04 Not applicable Colombia 
MUCOSOLVAN COMPOSITUM JARABE ADULTOS Ambroxol hydrochloride (300 mg) + Clenbuterol (0.2 mg) Syrup Oral PHARMETIQUE S.A. 2006-11-10 2021-04-01 Colombia MUCOSOLVAN COMPOSITUM JARABE PEDIATRICO. 7.5 MG / 0.005MG / 5ML. Ambroxol hydrochloride (0.15 g) + Clenbuterol hydrochloride (0.1 mg) Syrup Oral PHARMETIQUE S.A. 2006-11-10 2018-02-20 Colombia Mucospas - Saft Ambroxol hydrochloride (7.5 mg/5ml) + Clenbuterol hydrochloride (0.005 mg/5ml) Solution Oral Opella Healthcare Austria Gmb H 1987-03-12 Not applicable Austria 
Mucospas - Tabletten Ambroxol hydrochloride (30 mg) + Clenbuterol hydrochloride (0.02 mg) Tablet Oral Opella Healthcare Austria Gmb H 1987-03-12 Not applicable Austria
Categories
- ATC Codes
- R02AD05 — AmbroxolR03CC63 — Clenbuterol and ambroxol
- R03CC — Selective beta-2-adrenoreceptor agonists
- R03C — ADRENERGICS FOR SYSTEMIC USE
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- Drug Categories
- Adrenergics for Systemic Use
- Amines
- Anesthetics
- Anesthetics, Local
- Aniline Compounds
- Cough and Cold Preparations
- Cyclohexanes
- Cyclohexylamines
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Drugs for Obstructive Airway Diseases
- Expectorants
- Respiratory System Agents
- Selective Beta 2-adrenergic Agonists
- Throat Preparations
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylmethylamines
- Direct Parent
- Phenylmethylamines
- Alternative Parents
- Benzylamines / 2-bromoanilines / Cyclohexylamines / Cyclohexanols / Bromobenzenes / Aralkylamines / Aryl bromides / Cyclic alcohols and derivatives / Dialkylamines / Primary amines show 3 more
- Substituents
- 2-bromoaniline / Alcohol / Amine / Aniline or substituted anilines / Aralkylamine / Aromatic homomonocyclic compound / Aryl bromide / Aryl halide / Benzylamine / Bromobenzene show 17 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 200168S0CL
- CAS number
- 18683-91-5
- InChI Key
- JBDGDEWWOUBZPM-XYPYZODXSA-N
- InChI
- InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2/t10-,11-
- IUPAC Name
- (1r,4r)-4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol
- SMILES
- NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1
References
- Synthesis Reference
Kack, J., Koss, F.W., Schraven, E. and Beisenherz, G.; US. Patent 3,536,713; October 27, 1970; assigned to Boehringer lngelheim G.m.b.H.
- General References
- Not Available
- External Links
- PubChem Compound
- 2132
- PubChem Substance
- 347827790
- ChemSpider
- 10276826
- BindingDB
- 50395322
- 625
- ChEBI
- 135590
- ChEMBL
- CHEMBL153479
- ZINC
- ZINC000100070274
- Wikipedia
- Ambroxol
- MSDS
- Download (47.4 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Community Acquired Pneumonia (CAP) / Coronavirus Disease 2019 (COVID‑19) / Critically Ill Patients / Nosocomial Pneumonia / Severe Pneumonia 1 3 Completed Treatment Abnormal Mucus Secretions / Respiratory Tract Diseases 1 3 Completed Treatment Pharyngitis 4 3 Not Yet Recruiting Treatment Parkinson's Disease (PD) 1 2 Active Not Recruiting Treatment GBA Gene Mutation / Parkinson's Disease (PD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution 7.5 mg/ml Tablet, soluble Oral 30 mg Solution Oral 7.5 MG/ML Solution Oral 15 MG/ML Tablet, effervescent Oral Solution Oral; Respiratory (inhalation) 7.5 mg/ml Solution Oral 0.3 g Syrup Oral 600 mg Solution Oral 15 MG/5ML Tablet, for solution; tablet, for suspension Oral 30 MG Tablet, effervescent Oral 60 MG Syrup Oral 600 g Tablet, soluble Oral 60 mg Solution Oral 3 mg/ml Elixir Oral 30 MG/5ML Solution Respiratory (inhalation) 7.5 mg/mL Syrup Oral 0.6 g Syrup Oral 60000000 mg Syrup Oral 300 mg Injection, solution Parenteral 15 MG/2ML Tablet Oral 60 MG Syrup Oral 0.3 g Granule, for suspension Oral Tablet, extended release Oral Spray Oral Solution 300.000 mg Solution Oral 0.6 g Solution Oral 300.0000 mg Solution Intramuscular 15.000 mg Suspension Oral Suspension Tablet Oral 30.000 mg Tablet Oral Tablet Oral Syrup Oral Solution / drops; suspension / drops 7.5 MG/ML Granule, for solution Oral 65 mg Granule, for suspension Oral 30 MG Solution Oral 0.75 % Solution Respiratory (inhalation) 15 MG/2ML Spray 15 MG/2ML Suppository Rectal 30 mg Granule Oral Spray Suppository Rectal Tablet Syrup Oral 3 MG/ML Syrup Oral 30 MG/10ML Capsule Oral Tablet 31 MG Tablet Oral 20 mg Granule, for solution Oral Tablet Buccal 20.000 mg Spray Oral 17.86 mg/ml Lozenge Oral 20 MG Tablet Oral 30 mg Liquid Oral Capsule, extended release Oral Solution Intravenous 15 mg/2ml Granule, for solution Oral 15 MG Granule, for solution Oral 30 MG Granule, for solution Oral 60 MG Solution Parenteral 15.00 mg Solution Respiratory (inhalation) Spray 7.5 MG/ML Suppository Rectal 15 MG Suppository Rectal 60 MG Syrup Oral 200 ML Tablet, chewable Oral 15 MG Tablet, coated Oral 60 MG Capsule Oral 75 mg Capsule, delayed release Oral 75 mg Syrup Oral Tablet, film coated Oral 60 MG Granule Oral 2 g Solution Respiratory (inhalation) 15 MG Liquid Oral 30 mg/5mL Pastille Oral 15 MG Solution 7.5 mg/1ml Solution Respiratory (inhalation) 0.75 g Solution Oral 30 MG/2ML Solution Oral 0.750 g Solution / drops; suspension / drops Solution Oral 10 MG Syrup Oral 150 ml Solution Oral 300.00 mg Solution Oral Solution Oral 300 mg Solution Oral 300.000 mg Solution Oral 7.5 mg Spray Respiratory (inhalation) 15 MG/2ML Spray Respiratory (inhalation) 30 MG/4ML Syrup Oral 15 mg/mL Solution Intramuscular; Intravenous Elixir Oral 15 mg/5ml Lozenge Oral Solution Intravenous 1 G/50ML Suspension Oral 300 mg Solution Oral 0.3000 g Syrup Syrup Oral 0.15 g Solution Oral 750.000 mg Capsule Oral 30.000 mg Suspension Oral 0.2700 g Solution Oral Solution Oral 0.300 g Granule, effervescent Tablet, effervescent Oral 30 MG Solution Oral 6 MG/ML Spray Oral 2.5 MG Tablet Transmucosal Tablet Transmucosal 20 MG Spray Oral 15 MG/2ML Syrup Oral 15 mg/5mL Syrup Oral 30 mg/5mL Capsule, extended release Oral 75 mg Lozenge Oral 15 mg Tablet 30 mg Tablet, coated Oral 30 mg Solution Oral 30 mg/5ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 233-234.5 Kack, J., Koss, F.W., Schraven, E. and Beisenherz, G.; US. Patent 3,536,713; October 27, 1970; assigned to Boehringer lngelheim G.m.b.H. - Predicted Properties
Property Value Source Water Solubility 0.0185 mg/mL ALOGPS logP 3.72 ALOGPS logP 2.65 Chemaxon logS -4.3 ALOGPS pKa (Strongest Acidic) 15.26 Chemaxon pKa (Strongest Basic) 9.01 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 58.28 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 81.94 m3·mol-1 Chemaxon Polarizability 32.8 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-02ta-8029000000-8223c803de340f8e8fe9 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0029000000-0d55218ce7d65b7096d8 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-004j-1697000000-8b0734e20916cf9d08c9 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0009000000-135b59221d032f784217 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-076r-3098000000-c24ddfc154ebfb78b69c Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-01qa-9352000000-86c766d6ca5bc2e8eaba Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9101000000-1ad2659ed4ee6fd1d89e Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 164.98965 predictedDeepCCS 1.0 (2019) [M+H]+ 167.34764 predictedDeepCCS 1.0 (2019) [M+Na]+ 173.4408 predictedDeepCCS 1.0 (2019)
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Ishiguro N, Senda C, Kishimoto W, Sakai K, Funae Y, Igarashi T: Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica. 2000 Jan;30(1):71-80. [Article]
Drug created at September 01, 2010 19:05 / Updated at November 03, 2023 23:48